U.S. Markets close in 53 mins.

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
83.03-0.24 (-0.29%)
As of 3:07PM EDT. Market open.
People also watch
Full screen
Previous Close83.27
Bid83.08 x 200
Ask83.09 x 400
Day's Range83.01 - 84.28
52 Week Range63.76 - 86.27
Avg. Volume9,365,871
Market Cap108.43B
PE Ratio (TTM)9.02
Earnings DateN/A
Dividend & Yield2.08 (2.53%)
Ex-Dividend Date2017-09-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com4 hours ago

    Now That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?

    In the fight against cancer, CAR T therapies are growing in popularity. Butler and Cha surveyed 25 hematologists/oncologists about their thoughts on potentially using CAR T therapy in appropriate patients within their practices, beginning before the Gilead-Kite Pharma deal was announced, and the results appear to be good news. From the note: Our findings suggest that the majority of surveyed hematologists/oncologists are familiar with CAR T therapy, and plan to use the therapy for either r/r ALL [relapsed and refractory acute lymphoblastic leukemia] or r/r DLBCL [diffuse large B-cell lymphoma] patients.

  • Oddly, Juno Therapeutics Is Jumping 11.3% Today
    Motley Fool3 days ago

    Oddly, Juno Therapeutics Is Jumping 11.3% Today

    Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.

  • Gilead's (GILD) Epclusa Receives Label Expansion in Canada
    Zacks3 days ago

    Gilead's (GILD) Epclusa Receives Label Expansion in Canada

    Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.